Reprogramming of macrophage by metabolically engineered stem cell-derived exosome for the treatment of rheumatoid arthritis
발표자
()
초록
내용
Rheumatoid arthritis (RA) is a representative chronic autoimmune disease that affects the swelling and deformity of the joint. Infiltrating macrophages in the lining of the synovial joints are important mediators of inflammation in RA via secreting a variety of pro-inflammatory cytokines and chemokines. Reprogramming macrophages to an M2-like phenotype using mesenchymal stem cell-derived exosomes has emerged as a promising therapeutic strategy for RA. However, exosomes have poor circulation properties, limiting their therapeutic potential. Therefore, we developed surface-modified exosomes with dextran sulfate(Exo@DS), a substance targeting M1-like macrophages, through metabolic glycoengineering. Compared to modified exosomes through other methods, Exo@DS was readily obtained in high yields from metabolically engineered stem cells while retaining biological functions. Exo@DS effectively accumulated in inflamed joints and achieved enhanced therapeutic efficacy with the 10 times lower dosage of the unmodified exosomes.